Eli Frakes, PhD, Scientific Director of Women’s Health in US Medical Affairs at AbbVie discusses data that AbbVie presented at the American College of Obstetricians and Gynecologists (ACOG) Clinical and Scientific Meeting 2022 on the use of ORILISSA ® (elagolix) 200mg BID with hormonal add-back therapy, or the “adding back” of a small amount of estradiol and/or progestogens to help reduce potential side effects of treatment, for moderate-to-severe endometriosis-associated pain (EAP).
Eli Frakes is the Scientific Director of Women’s Health in US Medical Affairs at AbbVie. He has broad medical affairs experience supporting both US and global markets. Eli obtained his PhD in pharmacology with a focus in basic science of pain mechanisms from the University of Iowa and completed an Executive Certificate in the Business of Life Sciences at the Kelley Business School of Indiana University. He graduated from Buena Vista University with a double major in Biology and Chemistry.